I wish all people with MS could attend a CAN DO Program. I doubt there is anything, anywhere that even comes close to the quality and quantity of information and concern that was displayed. Thank you very much!

Paris, France - October 5, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine(NEJM). Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions. Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo.

The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 people with relapsing forms of MS from 126 centers across 21 countries. TEMSO is the first study from a broad clinical development program that includes more than 4,000 trial participants in 36 countries and is one of the largest and broadest clinical programs of any oral MS agent under development, with five Phase III clinical trials either completed or underway.

“The publication of the teriflunomide results in the New England Journal of Medicine is an exciting milestone as we continue the development of our product,” said Dr. Elias Zerhouni, President, Global Research & Development, Sanofi. "As we continue our commitment to research, innovation and the Multiple Sclerosis community, we look forward to providing therapeutic options for patients across the Multiple Sclerosis spectrum.”

Teriflunomide has been filed with the FDA in August of 2011 and the EMA filing is expected in the first quarter of 2012. The results from the TEMSO study are and will be included in each regulatory submission.

Significantly increased the time to first relapse, and allowed significantly more trial participants to remain free of relapses during the two years of the study: 53.7% (7mg, p=0.01 vs. placebo), 56.5% (14mg, p=0.003 vs. placebo) and 45.6% (placebo).

The risk of 12-week confirmed disability progression, the key secondary endpoint, was significantly reduced by 30% (p=0.03) for the 14mg dose and numerically reduced by 24% (p=0.08) for the 7mg dose.

Improved several standard magnetic resonance imaging (MRI) measures of disease activity as compared to placebo including new or worsening brain lesions with an apparent dose dependent effect in favor of the 14mg dose:

Similar adverse events, serious adverse events, and adverse events leading to treatment discontinuation were observed with teriflunomide compared to placebo. No serious or opportunistic infections and no deaths occurred in trial participants treated with teriflunomide. The proportion of participants who discontinued the study medication because of disease progression was significantly smaller in the group receiving the 14mg of teriflunomide than in the placebo group (p=0.02). Malignancies were reported in three participants in the placebo group and one in the teriflunomide 14mg group.

Teriflunomide adverse events were usually of mild to moderate intensity, managed with existing therapies and rarely led to treatment discontinuation. The most common were diarrhea, nausea, liver enzyme increases (that were mainly mild and asymptomatic with no dose effect) and mild hair thinning/decreased hair density. In general, diarrhea, nausea and alopecia, were mild to moderate, transient, and infrequently led to treatment discontinuation.

***

About Teriflunomide

Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation for the treatment of MS. Teriflunomide blocks the proliferation and functioning of activated T and B lymphocytes – which are thought to be especially damaging in MS – by selectively and reversibly inhibiting a critical mitochondrial enzyme. Slowly dividing or resting lymphocytes are unaffected by teriflunomide, leaving the immune system’s response to infection uncompromised. With nine years of continuous use in a Phase II extension, teriflunomide has the longest clinical experience of any investigational oral MS therapy. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in people with RMS. A Phase III study, TOPIC, is also underway in early MS or CIS (clinically isolated syndrome). Teriflunomide is also being evaluated as an adjunct therapy to interferon-? in the Phase III TERACLES trial.

(*) Aubagio™ is the registered name submitted to health authorities for the investigational agent teriflunomide.

About Multiple Sclerosis

Today more than 2,000,000 people around the world suffer from MS, a chronic autoimmune disease that affects the central nervous system – the brain, spinal cord and optic nerves. In MS, immune cells called lymphocytes mistakenly attack myelin, the fatty “insulation” that surrounds and protects nerves, resulting in abnormal nerve transmission and MS symptoms such as fatigue, weakness, walking and balance problems, vision problems, pain, spasticity and cognitive difficulties. MS is the most common disabling neurological disease in young adults after accidents, and is two to three times more common in women than in men. MS is usually characterized by relapses followed by periods of complete or incomplete recovery. There is no typical individual with MS, as the disease is a very variable condition and the symptoms depend on which areas of the central nervous system are affected. MS symptoms can vary from time to time and can change in severity and duration, even in the same person.The vast majority of people with MS – approximately 90 percent – are initially diagnosed with a relapsing form of MS.

Magnetic resonance imaging (MRI) is a common and important tool used to help establish a diagnosis of MS and monitor the course of the disease and effects of treatment. Providing a highly sensitive, non-invasive way to image the brain, spinal cord or, other areas of the body, MRI has made it possible to visualize and understand a great deal about the underlying pathology of MS.

About Genzyme, a Sanofi Company

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since its founding in 1981, the company has introduced breakthrough treatments that have provided new hope for patients. The company’s areas of focus are rare genetic diseases, multiple sclerosis, cardiovascular disease, and endocrinology. Genzyme is a Sanofi company. Genzyme’s press releases and other company information are available at www.genzyme.com.

Genzyme’s Multiple Sclerosis business unit is responsible for the development of teriflunomide, along with the investigational MS therapy alemtuzumab.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Formerly The Heuga Center for Multiple Sclerosis | Founded by Jimmie Heuga

A national nonprofit organization, Can Do MS is a leading provider of innovative lifestyle empowerment programs
that empower people with MS and their support partners to transform and improve their quality of life.

You must read the following terms and conditions of the Rolex "100" Raffle and accept to purchase a ticket.

Each purchaser of a raffle ticket must be at least 18 years old and only one individual's name may be associated with each ticket. All federal, state and local rules shall apply to the raffle. Tickets may be purchased by e-mail, from the website or in person from a Can Do MS staff or board member. Payments for online tickets may only be by credit card. Any credit or debit card payment that is denied shall disqualify the pending purchase and any ticket issued for such purchase will be forfeited by the purchaser. All online ticket sales shall be by the internet at the raffle website www.mscando.org/rolexraffle. All e-mail communications will be sent to the e-mail address provided by a purchaser as part of the purchase. Such communications shall include purchase confirmation and raffle ticket number. Purchaser is required to provide to Can Do MS ("Raffle Sponsor") a valid, functioning e-mail address and mailing address. The Raffle Sponsor, its processing agent and their respective directors, officers, and members assume no responsibility for incorrect, invalid, terminated or non-functioning e-mail or mailing addresses or lost, incomplete, late, illegible, or undelivered entries or entries without complete, acceptable payment.

By submitting an entry, each purchaser acknowledges having read and agreed to abide by these Official Raffle Rules.

Once a ticket has been purchased, it is non-refundable except in event the raffle is cancelled in accordance with the raffle regulations of the Colorado Secretary of State. Although a ticket may be transferred, the Raffle Sponsor shall communicate only with the ticket purchaser as shown on its records until proof of the ticket transfer is provided to the Raffle Sponsor. Any transferee of a ticket must be eligible under these Rules in order to win under any drawing. Odds of winning depend on the number of tickets sold. The maximum number of tickets sold is 100. The odds of winning the watch would be 1:100 if 100 tickets are sold. Odds decrease as more tickets are purchased.

The winner will receive the prize, subject to all applicable taxes and delivery fees. The price of any raffle tickets is not tax-deductible. As a general matter, federal and state income tax can be between 25% to 40% of the value of the raffle prize. Please consult with your own tax advisor. The winner will be entirely and solely responsible for paying any such taxes. A W-9 will need to be completed by the winner and received by Can Do MS prior to shipping of the item or receipt of the item by the winner.

Each ticket shall be sequentially numbered from the first ticket sold through the last ticket number sold. The raffle period shall be from the date the first ticket is sold, through December 2, 2013 or such earlier date as the maximum number of tickets is sold. Online ticket sales will be closed at any time before the drawing. The drawing will be held on Monday, December 2, 2013. Ticket purchase deadlines, and drawing dates, times and locations, may be extended or changed at the Raffle Sponsor's discretion, subject to approval of the Colorado Secretary of State.

Each online purchaser will be sent a ticket and receipt via e-mail that will identify the purchaser's unique raffle ticket number(s).The original printed raffle ticket will be retained by the Raffle Sponsor and the stub entered into the drawing along with the stubs of all other tickets sold. U.S. Postal regulations prohibit the mailing of raffle tickets.

At the raffle drawing, the winning raffle ticket stub shall be chosen by picking it from a large container containing all ticket stubs, thoroughly mixed. The drawing shall take place at 12:30 pm MDT on Monday, December 2, 2013 at the Can Do MS offices (27 Main Street, Suite 303, Edwards, Colorado, 81632). The winner does not need to be present at the drawing to win.

The holders of the winning ticket shall be notified by telephone and/or e-mail. The watch will be sent Certified U.S. Mail to the address provided by the purchaser. The winning ticket number and name of the winner and their respective cities (but not addresses) shall also be placed on the Raffle website immediately after the drawing. This information may also be publicized in other media.

The winner of the drawing shall be required to provide the Raffle Sponsor with a signed IRS
W-9 Request for Taxpayer Identification Number and Certification form. Winner will be asked to grant the Raffle Sponsor permission to use the winner's name, city, state, and likeness in media releases and other publicity.

The prize will be awarded in its then present, "as is", condition. The winner of the Rolex watch cannot trade the received watch for a different style.

Purchasers of tickets, by participating in the raffle, release the Raffle Sponsor, its directors, officers, members and agents from any and all liability, loss or claim arising out of any raffle prize, expressly waive any such claim and agree that the liability, if any, of the Raffle Sponsor, its directors, officers, members and agents shall be limited to the raffle ticket price paid. In case of any dispute regarding the conduct of the raffle, the decision of the Raffle Sponsor shall be final. The courts of Eagle County, Colorado shall have exclusive jurisdiction and venue for any dispute concerning the raffle.

OUR LEGACY IS OUR FUTURE.Give a gift in honor of our founder Jimmie Heuga'slegacy, and help us keep his vision alive.Donate to our Year-End Campaign before December 31st.